focus -WSS

focus

author：hotspot 2025-08-27 19:00:02 - browse：47

Sutter Health Palo Alto Medical Foundation facilities. health tech coverage from STAT — Adobe

When Sutter Health was on trial for anticompetitive conduct in 2022, the San Francisco jury missed out on some crucial details. They didn’t hear, for example, how its former finance chief said the system would make an extra $200 million per year by making insurers contract with all of its hospitals instead of just a few. Or how its former CEO said, “Related to the health plans, we force them to pay us more.”

That evidence was indeed relevant, and the judge erred by not allowing it to be presented during the month-long trial that concluded in March 2022, a U.S. appeals court wrote in its ruling on Tuesday. The Ninth Circuit panel overturned Sutter’s win in the class-action case alleging that Sutter used its market power to drive up health care costs across the region by more than $400 million. Tuesday’s decision means the case will likely get a second trial.

“Effectively, the appellate court said the jury was tainted,” said Matthew Cantor, lead counsel for the plaintiffs. “So the jury’s verdict is discarded.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： UnitedHealth, Optum discontinue NaviHealth name

entertainment

WSS

Why a market frenzy over new weight loss drugs defies logic

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Kenai launches with $82 million for Parkinson’s stem cell therapy

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

RSV vaccines may be linked to small increased risk of developing GBS

FDA does about

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

explore

Virginia high school admissions case could be legal follow

STAT Summit: Ending the crisis of Black deaths in the U.S.

Heart attack and stroke risk calculators need revising

In search for therapies for solid tumors, companies turn to claudin

Jerome Adams on the need for new antivirals for Covid

Results on Novartis prostate cancer therapy could expand its use

United colonoscopy coverage change 'may cost lives,' doctors say

International team creates first chimeric human

Affirmative action in medical school literally saved lives

STAT Readout: Friday, Oct. 20 biotech updates

leisure time

Roche drug slashes death risk in early

Change Healthcare cyberattack outage could last weeks

Change Healthcare cyberattack outage could last weeks

RaDonda Vaught to speak at CommonSpirit event on patient safety

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

In search for therapies for solid tumors, companies turn to claudin

focus

entertainment

Wikipedia

entertainment